EUVIMEDEUVIMED entdecken
Crossref

AFSP expert touts promise of ketamine‐buprenorphine approach

Valerie A. Canady

Mental Health Weekly · 25.05.2026 · 36 (21) · 6-7

DOI: 10.1002/mhw.34881 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mental Health Weekly, online erschienen am 21.05.2026. Verfasst von Valerie A. Canady.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New findings published this month in The American Journal of Psychiatry (AJP) on the use of ketamine followed by ultra‐low‐dose buprenorphine to sustain reductions in suicidal ideation are drawing attention from suicide prevention experts, who say the approach may help address a long‐standing gap in treatment during high‐risk periods following a crisis (see related story, p. 3).

Zitieren

APA

Canady, V. A. (2026). AFSP expert touts promise of ketamine‐buprenorphine approach. Mental Health Weekly, 36(21), 6-7. https://doi.org/10.1002/mhw.34881

Vancouver

Canady VA. AFSP expert touts promise of ketamine‐buprenorphine approach. Mental Health Weekly. 2026;36(21):6-7. doi:10.1002/mhw.34881

BibTeX
@article{Canady2026,
  author = {Canady, Valerie A.},
  title = {AFSP expert touts promise of ketamine‐buprenorphine approach},
  journal = {Mental Health Weekly},
  year = {2026},
  volume = {36},
  number = {21},
  pages = {6--7},
  doi = {10.1002/mhw.34881}
}
Kostenlos starten →